Gilead Sciences received FDA endorsement and product approvals in Norway, Iceland, and Liechtenstein on August 27, 2025, while navigating Trump's tariffs.
3 reports, 3 independent
Updated Jun 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences received FDA endorsement and product approvals in Norway, Iceland, and Liechtenstein on August 27, 2025, while navigating Trump's tariffs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Trodelvy received approvals from the FDA and European Commission, expanding its global reach.1 source
Gilead product approvals in Norway, Iceland, and Liechtenstein, while contending with Trump's tariff threats.1 source
Gilead Sciences expands market reach with EC approval and plans for new countries.1 source
Keep exploring
The entities involved
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
Coverage
Newest first; wire copies grouped- yahoo.com
- Simply Wall St.The Bull Case For Gilead Sciences (GILD) Could Change Following European Approval of Twice-Yearly HIV Prevention Injection Gilead Sciences announced that the European Commission has granted marketing
- Investing.comGilead wins European approval for HIV prevention injection Investing.com -- Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its twice-yearly injection